Efficacy of Docetaxel Plus Ramucirumab for Malignant Pleural Effusion and Cerebral Edema in Patients With Advanced Non‐Small Cell Lung Cancer: A Single‐Institution Retrospective Study
Thoracic Cancer · 2026-05 · 17 (9)
DOI: 10.1111/1759-7714.70295 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 01.05.2026. Verfasst von Meiko Morita und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Docetaxel, Pleural Effusion, Malignant, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Malignant pleural effusion (MPE) is associated with a poor prognosis and quality of life in patients with non‐small cell lung cancer (NSCLC). Additionally, cerebral edema can lead to neurological symptoms that adversely affect activities of daily living. While bevacizumab has demonstrated efficacy in treating both MPE and cerebral edema, there is limited research on ramucirumab, an angiogenesis inhibitor. Therefore, this study aimed to evaluate the efficacy of docetaxel combined with ramucirumab for the management of MPE and cerebral edema.
Methods
We retrospectively analyzed medical records of patients with advanced NSCLC who received docetaxel in conjunction with ramucirumab at Shizuoka Cancer Center between August 2016 and March 2023. The primary endpoints were pleural effusion progression‐free survival (PE‐PFS) and the cerebral edema control rate. Secondary endpoints included response rate, progression‐free survival (PFS), overall survival (OS), and the incidence of toxicities.
Results
A total of 163 patients were included. The median PE‐PFS was 8.1 months (95% CI: 4.8–12.0 months). The pleural effusion control rate was 87%, whereas the cerebral edema control rate was 26%. The response rate was 26%, with a median PFS of 4.4 months (95% confidence interval [CI]: 3.7–5.1 months) and a median OS of 11.1 months (95% CI: 9.2–16.0 months). Adverse events leading to discontinuation of treatment occurred in 30% of patients for docetaxel and 33% for ramucirumab, with fatigue being the most common reason for discontinuation.
Conclusion
Docetaxel plus ramucirumab was effective in controlling pleural effusion but showed limited effects on cerebral edema.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
ORCID-Profile: Kazushige Wakuda, Keita Miura, Nobuaki Mamesaya, Tateaki Naito, Haruyasu Murakami
Zitieren
APA
Morita, M., Wakuda, K., Matsuda, S., Sekikawa, M., Miura, K., Kodama, H., Yabe, M., Mamesaya, N., Kobayashi, H., Ko, R., Ono, A., Kenmotsu, H., Naito, T., Murakami, H., & Takahashi, T. (2026). Efficacy of Docetaxel Plus Ramucirumab for Malignant Pleural Effusion and Cerebral Edema in Patients With Advanced Non‐Small Cell Lung Cancer: A Single‐Institution Retrospective Study. Thoracic Cancer, 17(9). https://doi.org/10.1111/1759-7714.70295
Vancouver
Morita M, Wakuda K, Matsuda S, Sekikawa M, Miura K, Kodama H, et al. Efficacy of Docetaxel Plus Ramucirumab for Malignant Pleural Effusion and Cerebral Edema in Patients With Advanced Non‐Small Cell Lung Cancer: A Single‐Institution Retrospective Study. Thoracic Cancer. 2026;17(9). doi:10.1111/1759-7714.70295
BibTeX
@article{Morita2026,
author = {Morita, Meiko and Wakuda, Kazushige and Matsuda, Suguru and Sekikawa, Motoki and Miura, Keita and Kodama, Hiroaki and Yabe, Michitoshi and Mamesaya, Nobuaki and Kobayashi, Haruki and Ko, Ryo and Ono, Akira and Kenmotsu, Hirotsugu and Naito, Tateaki and Murakami, Haruyasu and Takahashi, Toshiaki},
title = {Efficacy of Docetaxel Plus Ramucirumab for Malignant Pleural Effusion and Cerebral Edema in Patients With Advanced Non‐Small Cell Lung Cancer: A Single‐Institution Retrospective Study},
journal = {Thoracic Cancer},
year = {2026},
volume = {17},
number = {9},
doi = {10.1111/1759-7714.70295}
}
EUVIMED